A case of enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction which was successfully treated with somatostatin analogue

Clin J Gastroenterol. 2022 Apr;15(2):363-367. doi: 10.1007/s12328-021-01581-6. Epub 2022 Jan 4.

Abstract

We report here a case of a 62-year-old woman with multiple gastric enterochromaffin-like cell neuroendocrine tumor caused by hypergastrinemia due to parietal cell dysfunction that was successfully treated with somatostatin analogue. Esophagogastroduodenoscopy revealed several G1 neuroendocrine tumors, 10 mm in diameter, in the body of the stomach. No evidence of autoimmune gastritis, Helicobacter pylori infection, neuroendocrine neoplasia type 1, or Zollinger-Ellison syndrome was identified. The pattern of immunohistochemical staining of the background gastric mucosa was suggestive of parietal cell dysfunction. She was treated with long-acting release octreotide acetate. Complete response was confirmed after 9 months and was maintained for 22 months.

Keywords: Enterochromaffin-like cell neuroendocrine tumor; Hypergastrinemia; Parietal cell dysfunction; Somatostatin analogue.

Publication types

  • Case Reports

MeSH terms

  • Enterochromaffin-like Cells / pathology
  • Female
  • Gastric Mucosa / pathology
  • Gastrins
  • Helicobacter Infections* / complications
  • Helicobacter pylori*
  • Humans
  • Middle Aged
  • Neuroendocrine Tumors* / complications
  • Neuroendocrine Tumors* / drug therapy
  • Somatostatin / therapeutic use
  • Stomach Neoplasms* / complications
  • Stomach Neoplasms* / drug therapy

Substances

  • Gastrins
  • Somatostatin